MPLT (MapLight Therapeutics) Total Liabilities: $18.95 Mil (As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Total Liabilities?

MapLight Therapeutics MPLT +3.09% 14 Total Liabilities is $18.95 Mil as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

MapLight Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $18.95 Mil.

MapLight Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($23.71 Mil) to Dec. 2025 ($21.14 Mil) and declined from Dec. 2025 ($21.14 Mil) to Mar. 2026 ($18.95 Mil).

MapLight Therapeutics's annual Total Liabilities increased from Dec. 2023 ($20.13 Mil) to Dec. 2024 ($21.72 Mil) but then declined from Dec. 2024 ($21.72 Mil) to Dec. 2025 ($21.14 Mil).

MapLight Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Total Liabilities Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
18.52 20.13 21.72 21.14

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.57 20.36 23.71 21.14 18.95
MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MapLight Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.229+(4.911+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=21.14

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=479.512-458.372
=21.14

MapLight Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.283+(4.671+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=18.95

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=418.788-399.834
=18.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $18.95 Mil mean?
MapLight Therapeutics (MPLT) has a Total Liabilities of $18.95 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MapLight Therapeutics and its competitors.
Is MapLight Therapeutics' Total Liabilities too high?
MapLight Therapeutics' current Total Liabilities is $18.95 Mil. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Total Liabilities compare to COAG and CAPR?
MapLight Therapeutics' Total Liabilities of $18.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MapLight Therapeutics and its competitors. MapLight Therapeutics's current Total Liabilities is $18.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Total Liabilities of $18.95 Mil. The current Total Liabilities is $18.95 Mil. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Total Liabilities is $18.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price